Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)- A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Study Summary
- This study aims to look at how Non-Small Cell Lung Cancer (NSCLC) patients respond to Nivolumab after surgical resection and adjuvant chemotherapy
- Patients will be randomized 1:1, like the flip of a coin, to receive Nivolumab or to be followed for observation
- For the patients that will receive Nivolumab, it will be given in cycles that last 2 weeks each. This treatment will continue for up to one year (26 cycles)

Protocol
- EA5142

Phase
- III

Investigator
- Dr. Kenneth Blankstein

Disease
- Non-Small Cell Lung Cancer (NSCLC)

Clinical Trials.gov
- https://clinicaltrials.gov/ct2/show/NCT02595944?term=EA5142&rank=1

Inclusion
- Must have undergone a surgical resection of stage IB, II or IIA NSCLC and have had negative surgical margins
- Must have completed and recovered from any adjuvant chemotherapy 2 or more weeks before registered
- Must be 18 years old or older and be able to carry out most daily tasks on his or her own (ECOG must be 0 or 1)

Exclusion
- Prior treatment with an immune checkpoint inhibitor
- A history of interstitial lung disease that is symptomatic or any autoimmune diseases
- Cannot be on a daily dose of corticosteroids equivalent to >10 mg of prednisone per day
If you have any questions regarding this study or think that you or your loved one may be eligible, please feel free to contact:

Kaitlyn Singer  
908-237-2330 ex 3  
ksinger@hhsnj.org

Serena Schmitz  
908-237-2330 ex 2  
sschmitz@hhsnj.org